Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma.

LMO2 regulates gene expression by facilitating the formation of multipartite DNA-binding complexes. In B cells, LMO2 is specifically up-regulated in the germinal center (GC) and is expressed in GC-derived non-Hodgkin lymphomas. LMO2 is one of the most powerful prognostic indicators in diffuse large B-cell (DLBCL) patients. However, its function in GC B cells and DLBCL is currently unknown. In this study, we characterized the LMO2 transcriptome and transcriptional complex in DLBCL cells. LMO2 regulates genes implicated in kinetochore function, chromosome assembly, and mitosis. Overexpression of LMO2 in DLBCL cell lines results in centrosome amplification. In DLBCL, the LMO2 complex contains some of the traditional partners, such as LDB1, E2A, HEB, Lyl1, ETO2, and SP1, but not TAL1 or GATA proteins. Furthermore, we identified novel LMO2 interacting partners: ELK1, nuclear factor of activated T-cells (NFATc1), and lymphoid enhancer-binding factor1 (LEF1) proteins. Reporter assays revealed that LMO2 increases transcriptional activity of NFATc1 and decreases transcriptional activity of LEF1 proteins. Overall, our studies identified a novel LMO2 transcriptome and interactome in DLBCL and provides a platform for future elucidation of LMO2 function in GC B cells and DLBCL pathogenesis.

[1]  M. Kelliher,et al.  A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice , 2011, Oncogene.

[2]  Raja Jothi,et al.  Nuclear adaptor Ldb1 regulates a transcriptional program essential for the maintenance of hematopoietic stem cells , 2011, Nature Immunology.

[3]  Xiaoqing Lu,et al.  HGAL, a germinal center specific protein, decreases lymphoma cell motility by modulation of the RhoA signaling pathway. , 2010, Blood.

[4]  Rajendran Sanalkumar,et al.  Building multifunctionality into a complex containing master regulators of hematopoiesis , 2010, Proceedings of the National Academy of Sciences.

[5]  B. Göttgens,et al.  A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients , 2010, Oncogene.

[6]  Albert Gutierrez,et al.  LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. , 2010, Blood.

[7]  D. Curtis,et al.  The Molecular Basis of Lmo2-Induced T-Cell Acute Lymphoblastic Leukemia , 2010, Clinical Cancer Research.

[8]  C. D. de Graaf,et al.  The Lmo2 Oncogene Initiates Leukemia in Mice by Inducing Thymocyte Self-Renewal , 2010, Science.

[9]  I. Lossos,et al.  Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. , 2010, Blood.

[10]  Christian Buske,et al.  A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis , 2008, The Journal of experimental medicine.

[11]  Y. Yashiro‐Ohtani,et al.  Notch1 co-opts lymphoid enhancer factor 1 for survival of murine T-cell lymphomas. , 2007, Blood.

[12]  L. Staudt,et al.  Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell–like diffuse large B cell lymphoma , 2007, The Journal of experimental medicine.

[13]  I. Lossos,et al.  The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. , 2007, Blood.

[14]  V. Deleuze,et al.  TAL-1/SCL and Its Partners E47 and LMO2 Up-Regulate VE-Cadherin Expression in Endothelial Cells , 2007, Molecular and Cellular Biology.

[15]  Patrick Rodriguez,et al.  Novel binding partners of Ldb1 are required for haematopoietic development , 2006 .

[16]  Charles Lee,et al.  The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. , 2006, Blood.

[17]  J. Buerstedde,et al.  E2A Expression Stimulates Ig Hypermutation1 , 2006, The Journal of Immunology.

[18]  T. Hoang,et al.  ETO2 coordinates cellular proliferation and differentiation during erythropoiesis , 2006, The EMBO journal.

[19]  L. Pham,et al.  Constitutive NF-kappaB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival. , 2005, Blood.

[20]  P. Vyas,et al.  ETO-2 Associates with SCL in Erythroid Cells and Megakaryocytes and Provides Repressor Functions in Erythropoiesis , 2005, Molecular and Cellular Biology.

[21]  Tien Hsu,et al.  RNA-dependent integrin α3 protein localization regulated by the Muscleblind-like protein MLP1 , 2005, Nature Cell Biology.

[22]  Christopher J. Wilkinson,et al.  The Polo kinase Plk4 functions in centriole duplication , 2005, Nature Cell Biology.

[23]  C. Murre.  Helix-loop-helix proteins and lymphocyte development , 2005, Nature Immunology.

[24]  V. Diehl,et al.  The early transcription factor GATA‐2 is expressed in classical Hodgkin's lymphoma , 2004, The Journal of pathology.

[25]  Ash A. Alizadeh,et al.  Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.

[26]  T. Hoang,et al.  SCL Assembles a Multifactorial Complex That Determines Glycophorin A Expression , 2004, Molecular and Cellular Biology.

[27]  T. Rabbitts,et al.  The LMO2 T-Cell Oncogene Is Activated via Chromosomal Translocations or Retroviral Insertion during Gene Therapy but Has No Mandatory Role in Normal T-Cell Development , 2003, Molecular and Cellular Biology.

[28]  S. Kishikawa,et al.  Transcriptional regulation by zinc-finger proteins Sp1 and MAZ involves interactions with the same cis-elements. , 2003, International journal of molecular medicine.

[29]  Andrea Califano,et al.  Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. , 2003, The Journal of clinical investigation.

[30]  J. Kaiser.  Seeking the Cause of Induced Leukemias in X-SCID Trial , 2003, Science.

[31]  Erich A. Nigg,et al.  Centrosome aberrations: cause or consequence of cancer progression? , 2002, Nature Reviews Cancer.

[32]  T. Hoang,et al.  functional interaction with Sp 1 expression in hematopoietic cells through c-kit The SCL-complex regulates , 2002 .

[33]  T. Rabbitts,et al.  The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target , 2002, Oncogene.

[34]  T. Hoang,et al.  SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-Tα chain expression , 2000, Nature Immunology.

[35]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[36]  T. Rabbitts,et al.  The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[37]  C. Murre,et al.  E2A activity is induced during B‐cell activation to promote immunoglobulin class switch recombination , 1999, The EMBO journal.

[38]  O. Yoshie,et al.  TAL1 and LIM-Only Proteins Synergistically Induce Retinaldehyde Dehydrogenase 2 Expression in T-Cell Acute Lymphoblastic Leukemia by Acting as Cofactors for GATA3 , 1998, Molecular and Cellular Biology.

[39]  T. Rabbitts,et al.  The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  T. Rabbitts,et al.  The LIM‐only protein Lmo2 is a bridging molecule assembling an erythroid, DNA‐binding complex which includes the TAL1, E47, GATA‐1 and Ldb1/NLI proteins , 1997, The EMBO journal.

[41]  Y. Ono,et al.  Transcriptional Activity of TAL1 in T Cell Acute Lymphoblastic Leukemia (T-ALL) Requires RBTN1 or −2 and Induces TALLA1, a Highly Specific Tumor Marker of T-ALL* , 1997, The Journal of Biological Chemistry.

[42]  A. Goldfarb,et al.  Involvement of the E2A basic helix-loop-helix protein in immunoglobulin heavy chain class switching. , 1996, Molecular immunology.

[43]  M. Cleary,et al.  Helix-loop-helix proteins LYL1 and E2a form heterodimeric complexes with distinctive DNA-binding properties in hematolymphoid cells , 1996, Molecular and cellular biology.

[44]  T. Rabbitts,et al.  The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice. , 1995, Oncogene.

[45]  T. Rabbitts,et al.  Functional diversity of LIM proteins: amino-terminal activation domains in the oncogenic proteins RBTN1 and RBTN2. , 1995, Oncogene.

[46]  M. Evans,et al.  The Oncogenic Cysteine-rich LIM domain protein Rbtn2 is essential for erythroid development , 1994, Cell.

[47]  A. Nordheim,et al.  Activation of ternary complex factor Elk‐1 by MAP kinases. , 1993, The EMBO journal.

[48]  R. Baer.  TAL1, TAL2 and LYL1: a family of basic helix-loop-helix proteins implicated in T cell acute leukaemia. , 1993, Seminars in cancer biology.

[49]  T. Rabbitts,et al.  T-cell acute lymphoblastic lymphoma induced in transgenic mice by the RBTN1 and RBTN2 LIM-domain genes. , 1992, Oncogene.

[50]  M. Perutz,et al.  The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[51]  H. Clevers,et al.  Identification and cloning of TCF‐1, a T lymphocyte‐specific transcription factor containing a sequence‐specific HMG box. , 1991, The EMBO journal.

[52]  T. Rabbitts,et al.  The rhombotin gene belongs to a class of transcriptional regulators with a potential novel protein dimerisation motif. , 1990, Oncogene.

[53]  I. Lossos,et al.  B-cell lymphoma Identification of LMO2 transcriptome and interactome in diffuse large , 2012 .